Forgotten Dairies
Tylenol on Trial: When Politics Outruns Medical Science -By Fransiscus Nanga Roka
America has to investigate potential drug dangers ceaselessly. Turning one into the other by press conference is not prudence, it is public-health malpractice.
The Tylenol litigation is no longer just a tort case. It is a perilous American experiment on the question of whether judges, juries and politicians can separate scientific uncertainty from certainty.
Over 500 parents or guardians have filed lawsuits claiming prenatal exposure to acetaminophen, the active ingredient in Tylenol, was a factor in their children developing autism spectrum disorder or attention deficit/hyperactivity disorder. They call out the manufacturer Kenvue, its former parent Johnson & Johnson and big box retailers for not warning consumers.
In December 2024, US District Judge Denise Cote gutted the federal multidistrict litigation by striking the plaintiffs’ causation experts as lacking scientific reliability. This included methodological deficiencies, notably the selective consideration of epidemiological evidence. Claims of causation could not survive without admissible expert testimony.
However, this ruling on 13 July 2026 reinstated more than 500 lawsuits by the Second US Circuit Court of Appeals. Its unanimous panel maintained Cote wrongly barred three experts including Harvard School of Public Health Dean Andrea Baccarelli whose techniques parroted accepted scientific practices and reasonable readings of controversial evidence. The exclusions involving two other experts stayed in.
The ruling does not definitively find that Tylenol can cause autism or ADHD. It determines which expert may testify, not which side is scientifically right in the end. The cases are now back in front of Cote, where Kenvue will be able to mount its challenges again and where plaintiffs must still demonstrate exposure, general causation, individual causation, failure to warn and damages. The fact a jury is allowed to consider a hypothesis should never be confused with scientific validation.
However, that distinction has already been corrupted by politics.
Last September, President Donald Trump warned pregnant women off Tylenol, while Health Secretary Robert F. Kennedy Jr called the link ‘very suggestive’. The FDA began a label change for possible, though unproven, causation. Texas AG Ken Paxton then sued Kenvue and Johnson & Johnson for false advertising and hiding risk.
Litigants then become seekers not at all orderly for that butterfly net of responsibility but instead nets themselves where government leaders broadcast causation before science can show it. Pregnant women are scared off from one of the only safe and effective treatments for pain and fever while untreated maternal fever can threaten both mother and fetus.
The strongest evidence demands restraint. Consistent with our findings, ACOG continues to describe acetaminophen as the analgesic and antipyretic of choice during pregnancy when used in the lowest effective dose for the shortest period of time necessary as advised by a physician. It says that the current evidence does not prove causation. Associations largely disappeared in sibling-controlled studies, based on a very large Swedish cohort.
Yet the controversy has taken its toll. Just as Kimberly-Clark was working on its plan to buy Kenvue for >$40 bil., the shares became susceptible to political rhetoric and renewed lawsuits. Investors pricing liability are not technically trained epidemiologists, and share price declines are not biomedical propositions.
From a strategic perspective, courts must appoint neutral scientific experts, mandate systematic reviews that are transparent and distinguish case-specific from general causation. The FDA must disclose its evidentiary foundation and uncertainty analysis outside the choreography of the White House. There should be another hat, a separate research component dedicated to compliance that keeps regulatory science as free from political interference as possible. Kenvue should release all safety data, while plaintiffs must submit reproducible dose, timing and confounder analyses.
America has to investigate potential drug dangers ceaselessly. Turning one into the other by press conference is not prudence, it is public-health malpractice.
Fransiscus Nanga Roka
Faculty of Law University 17 August 1945 Surabaya and Managing Partner Law Firm Victorious Indonesia
